基于影像的[225Ac]Ac-PSMA-I&T治疗剂量测定及子体特异性药代动力学的影响
研究对5例接受[225Ac]Ac-PSMA-I&T治疗的患者行腹部SPECT/CT及尿液分析,探究221Fr与213Bi的药代动力学差异及其对基于影像的病灶和肾脏剂量测定的影响。结果显示子体特异性药代动力学差异最高约10%,对病灶和肾脏剂量测定的影响保持在8%以内。
要点
- 5例患者接受7.7±0.2 MBq [225Ac]Ac-PSMA-I&T,于24和48小时行腹部SPECT/CT。
- 213Bi与221Fr的肾脏SUV比值从24到48小时平均增加9%。
- 子体特异性药代动力学差异对病灶和肾脏剂量测定影响保持在8%以内。
核心结论
- SPECT/CT显像与尿液分析显示子体特异性药代动力学差异最高约10%,这些差异对病灶和肾脏剂量测定的影响保持在8%以内。
研究设计与样本
- 5例患者接受7.7±0.2 MBq [225Ac]Ac-PSMA-I&T治疗,于24和48小时行腹部SPECT/CT(Siemens Symbia T2,高能准直器,440 keV/218 keV(宽度20%)、78 keV(宽度50%))。
- 定量SPECT采用MAP-EM重建,包含衰减校正、透射依赖散射校正和分辨率建模;肾脏(基于CT)和病灶(24小时80%等轮廓)的时间-放射性曲线采用单指数拟合。
- 每次SPECT/CT同时收集尿液样本,在伽马计数器中测量至长期平衡。
主要发现
- 肾脏和病灶平均有效半衰期分别为:213Bi 27±6/38±10小时;221Fr 24±6/38±11小时;78 keV 23±7/39±13小时。
- 213Bi与221Fr的肾脏SUV比值从24到48小时平均增加9%。
- 尿液分析显示213Bi与225Ac比值升高(24小时0.98±0.15;48小时1.08±0.09)。
- 使用221Fr和213Bi SPECT图像时,肾脏和病灶平均吸收剂量分别为0.17±0.06和0.36±0.1 Sv RBE=5/MBq;仅考虑221Fr或213Bi SPECT时分别为0.16±0.05/0.18±0.06和0.36±0.1/0.38±0.1 Sv RBE=5/MBq。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Although 221Fr and 213Bi have sufficient gamma emission probabilities, quantitative SPECT after [225Ac]Ac-PSMA-I&T therapy remains challenging due to low therapeutic activities. Furthermore, 221Fr and 213Bi may underlie a different pharmacokinetics due to alpha recoil. We conducted a quantitative SPECT study and a urine analysis to investigate the pharmacokinetics of 221Fr and 213Bi and the impact on image-based lesion and kidney dosimetry. METHODS: Five patients (7.7 ± 0.2 MBq [225Ac]Ac-PSMA-I&T) underwent an abdominal SPECT/CT (1 h) at 24 and 48 h (Siemens Symbia T2, high-energy collimator, 440 keV/218 keV (width 20%), 78 keV (width 50%)). Quantitative SPECT was reconstructed using MAP-EM with attenuation and transmission-dependent scatter corrections and resolution modelling. Time-activity curves for kidneys (CT-based) and lesions (80% isocontour 24 h) were fitted mono-exponentially. Urine samples collected along with each SPECT/CT were measured in a gamma counter until secular equilibrium was reached. RESULTS: Mean kidney and lesion effective half-lives were as follows: 213Bi, 27 ± 6/38 ± 10 h; 221Fr, 24 ± 6/38 ± 11 h; 78 keV, 23 ± 7/39 ± 13 h. The 213Bi-to-221Fr kidney SUV ratio increased by an average of 9% from 24 to 48 h. Urine analysis revealed an increasing 213Bi-to-225Ac ratio (24 h, 0.98 ± 0.15; 48 h, 1.08 ± 0.09). Mean kidney and lesion absorbed doses were 0.17 ± 0.06 and 0.36 ± 0.1 Sv RBE = 5 /MBq using 221Fr and 213Bi SPECT images, compared to 0.16 ± 0.05/0.18 ± 0.06 and 0.36 ± 0.1/0.38 ± 0.1 Sv RBE = 5 /MBq considering either the 221Fr or 213Bi SPECT. CONCLUSION: SPECT/CT imaging and urine analysis showed minor differences of up to 10% in the daughter-specific pharmacokinetics. These variances had a minimal impact on the lesion and kidney dosimetry which remained within 8%.
引用
- Liubchenko G, Böning G, Zacherl M, et al. Image-based dosimetry for [225Ac]Ac-PSMA-I&T therapy and the effect of daughter-specific pharmacokinetics. Eur J Nucl Med Mol Imaging. 2024. PMID: 38512484. doi:10.1007/s00259-024-06681-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。